British journal of pharmacology · 2026
Priming with interleukin-1α and chemical hypoxia modulates the mesenchymal stem cell secretome to dampen microglial inflammation and promote neuroprotection.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Salaudeen Maryam Adenike, Allan Stuart M, Pinteaux Emmanuel
Аннотация
BACKGROUND AND PURPOSE: We hypothesised that dual priming of human bone marrow-derived human mesenchymal stem cells (hBMSCs) with interleukin-1alpha (IL-1α) and CoCl2 (a hypoxia mimetic) would modulate their therapeutic efficacy for hypoxic-ischaemic conditions.
EXPERIMENTAL APPROACH: hBMSCs were primed individually or in combination. To test the anti-inflammatory and cytoprotective properties, primed-hBMSCs-derived conditioned media (CM) was applied to lipopolysaccharide (LPS)-treated BV2 microglial cells (inflammation model) and BV2 cells exposed to oxygen glucose deprivation (OGD) (hypoxic injury model). The neuroprotective effect was evaluated by assessing neuronal death (using neuron-like cells [NLCs]) following exposure to OGD/reoxygenation (OGD/R) in the presence of various CMs.
KEY RESULTS: Priming significantly altered hBMSCs' secretion profiles. IL-1α triggered significant (P < 0.05) release of inflammatory mediators/cytokines, notably TNF-α, ICAM-1 and G-CSF. Except for G-SCF, dual-priming did not potentiate their release. While single priming with either IL-1α or hypoxia-mimetic did not induce remarkable secretion of the neurotrophins β-NGF and BDNF, the dual-priming caused a potentiated increase (P < 0.05) in the secretion of these neurotrophins. In the LPS model, CM from dual-primed hBMSCs significantly reduced the secretion of pro-inflammatory cytokines, TNF-α and IL-6. In the OGD/R model, priming did not significantly influence the marked reduction (P < 0.05) of pro-inflammatory cytokines IL-1β, IL-6 and TNF-α. Lastly, CMs from primed hBMSCs reduced neuronal cytotoxicity, yet only CM from dual-primed hBMSCs significantly (P < 0.05) restored metabolic activity in NLCs following OGD/R.
CONCLUSIONS AND IMPLICATIONS: These findings highlight dual priming as a promising strategy for optimising MSC-based approaches for hypoxic-ischaemic conditions.
EXPERIMENTAL APPROACH: hBMSCs were primed individually or in combination. To test the anti-inflammatory and cytoprotective properties, primed-hBMSCs-derived conditioned media (CM) was applied to lipopolysaccharide (LPS)-treated BV2 microglial cells (inflammation model) and BV2 cells exposed to oxygen glucose deprivation (OGD) (hypoxic injury model). The neuroprotective effect was evaluated by assessing neuronal death (using neuron-like cells [NLCs]) following exposure to OGD/reoxygenation (OGD/R) in the presence of various CMs.
KEY RESULTS: Priming significantly altered hBMSCs' secretion profiles. IL-1α triggered significant (P < 0.05) release of inflammatory mediators/cytokines, notably TNF-α, ICAM-1 and G-CSF. Except for G-SCF, dual-priming did not potentiate their release. While single priming with either IL-1α or hypoxia-mimetic did not induce remarkable secretion of the neurotrophins β-NGF and BDNF, the dual-priming caused a potentiated increase (P < 0.05) in the secretion of these neurotrophins. In the LPS model, CM from dual-primed hBMSCs significantly reduced the secretion of pro-inflammatory cytokines, TNF-α and IL-6. In the OGD/R model, priming did not significantly influence the marked reduction (P < 0.05) of pro-inflammatory cytokines IL-1β, IL-6 and TNF-α. Lastly, CMs from primed hBMSCs reduced neuronal cytotoxicity, yet only CM from dual-primed hBMSCs significantly (P < 0.05) restored metabolic activity in NLCs following OGD/R.
CONCLUSIONS AND IMPLICATIONS: These findings highlight dual priming as a promising strategy for optimising MSC-based approaches for hypoxic-ischaemic conditions.